Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

(2014) Sally F. Barrington et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era

(2013) Yu-Chung Huang et al.   ANNALS OF HEMATOLOGY

Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma

(2013) Nathalie Nols et al.   LEUKEMIA & LYMPHOMA

A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma

(2012) A. M. Perry et al.   BLOOD

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

(2012) P. Pregno et al.   BLOOD

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

(2012) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

(2011) Michael Pfreundschuh et al.   LANCET ONCOLOGY

Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors

(2010) C. A. Thompson et al.   ANNALS OF ONCOLOGY

Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

(2010) Craig H. Moskowitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

The Case Against Heavy PETing

(2009) Bruce Cheson   JOURNAL OF CLINICAL ONCOLOGY

Report on the First International Workshop on interim-PET scan in lymphoma

(2009) Michel Meignan et al.   LEUKEMIA & LYMPHOMA

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

(2008) H. S. Han et al.   ANNALS OF ONCOLOGY

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

(2008) J. Dupuis et al.   ANNALS OF ONCOLOGY

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

(2008) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS